Clinical trial
A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
NCT01786096 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas
- Lead sponsor
- Seagen Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 28, 2013
- Completion date
- May 30, 2017
- Enrollment
- 92 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.